#1 Clinical Trials Search in Europe

Fludarabine Phosphate

Fludarabine Phosphate, also known by brand names like Fludara, is a chemotherapy drug being studied in various clinical trials for its potential in treating different types of cancer, particularly blood cancers. This article explores the ongoing research into Fludarabine Phosphate’s efficacy, safety, and applications in cancer therapy.

Table of Contents

What is Fludarabine Phosphate?

Fludarabine Phosphate, also known by brand names such as Fludara[1], Beneflur[2], or BAY86-4864[1], is a medication used in the treatment of various blood cancers. It belongs to a class of drugs called purine nucleoside analogs, which work by interfering with the growth of cancer cells.

What Conditions Does Fludarabine Phosphate Treat?

Fludarabine Phosphate is primarily used to treat several types of blood cancers and related conditions, including:

  • Non-Hodgkin’s Lymphoma (NHL): A type of cancer that starts in the lymphatic system[1][3]
  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow[4]
  • Acute Myeloid Leukemia (AML): A type of cancer of the blood and bone marrow[4]
  • Myelodysplastic Syndrome (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells[4]

How Does Fludarabine Phosphate Work?

Fludarabine Phosphate works by interfering with the DNA synthesis of cancer cells. It is classified as an antimetabolite, which means it mimics natural substances needed for cell growth but actually blocks the process. This action prevents cancer cells from dividing and growing, ultimately leading to their death[1][1].

How is Fludarabine Phosphate Administered?

Fludarabine Phosphate can be administered in two main ways:

  1. Intravenous (IV) Infusion: The drug is given directly into a vein over a period of time, usually in a hospital or clinic setting[4].
  2. Oral Tablets: Some formulations allow patients to take Fludarabine Phosphate by mouth at home[1][3].

The dosage and duration of treatment depend on the specific condition being treated, the patient’s overall health, and response to the therapy. Typically, Fludarabine Phosphate is given in cycles, with periods of treatment followed by rest periods to allow the body to recover[1].

Clinical Trials and Research

Numerous clinical trials have been conducted to evaluate the effectiveness and safety of Fludarabine Phosphate. Some key findings include:

  • Efficacy in treating indolent (slow-growing) lymphomas[1]
  • Potential benefits when combined with other cancer drugs like Rituximab and Cyclophosphamide[2]
  • Effectiveness as part of conditioning regimens for stem cell transplants[4]

Potential Side Effects and Safety Considerations

Like all medications, Fludarabine Phosphate can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Fatigue
  • Weakened immune system, increasing the risk of infections
  • Low blood cell counts (anemia, neutropenia, thrombocytopenia)
  • Fever

Your healthcare team will monitor you closely during treatment and may adjust the dosage or provide supportive care to manage side effects[1][3].

Combination Therapy with Fludarabine Phosphate

Fludarabine Phosphate is often used in combination with other cancer drugs to enhance its effectiveness. Some common combinations include:

  • RFC (Rituximab, Fludarabine, Cyclophosphamide): This combination has shown promising results in treating follicular non-Hodgkin’s lymphoma[2].
  • Fludarabine and Busulfan: Used in conditioning regimens for stem cell transplants[4].
  • Fludarabine and Mitoxantrone: Studied for effectiveness in treating follicular non-Hodgkin’s lymphoma[3].

These combinations may offer improved outcomes for certain patients, but they may also come with additional side effects. Your doctor will discuss the best treatment approach based on your individual case[2][3][4].

Aspect Details
Primary Cancers Studied Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin’s Lymphoma (NHL), Indolent Lymphoma
Administration Methods Oral (tablets), Intravenous (injection)
Common Treatment Protocols 3-6 cycles, each cycle typically 28 days
Combination Therapies With mitoxantrone, rituximab; part of stem cell transplantation regimens
Key Outcome Measures Response rates, progression-free survival, overall survival, safety profile
Notable Applications Used in AHSCT for multiple sclerosis; investigated for head and neck cancer
Safety Considerations Monitoring for adverse events; potential for lowered blood counts and increased infection risk

FAQ

  • What types of cancer is Fludarabine Phosphate being studied for? Fludarabine Phosphate is primarily being studied for blood cancers such as chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and indolent lymphoma. It's also being investigated for use in stem cell transplantation for multiple sclerosis.
  • How is Fludarabine Phosphate administered? Fludarabine Phosphate can be administered both orally (as tablets) and intravenously (as an injection). The method of administration varies depending on the specific clinical trial and treatment protocol.
  • What are some common side effects of Fludarabine Phosphate? While specific side effects are not detailed in the provided trials, as with most chemotherapy drugs, Fludarabine Phosphate may cause side effects. These can include lowered blood counts, increased risk of infections, and fatigue. The trials are monitoring for adverse events to better understand its safety profile.
  • Is Fludarabine Phosphate used alone or in combination with other treatments? Fludarabine Phosphate is being studied both as a single agent and in combination with other treatments. For example, some trials are investigating its use in combination with drugs like mitoxantrone, rituximab, or as part of conditioning regimens for stem cell transplantation.
  • What is the typical duration of treatment with Fludarabine Phosphate in these trials? The duration of treatment varies across trials, but many involve multiple cycles of treatment. For instance, some trials administer Fludarabine Phosphate for 3-6 cycles, with each cycle typically lasting 28 days. However, the exact duration can depend on factors such as the patient's response and tolerance to the treatment.

Ongoing Clinical Trials on Fludarabine Phosphate

  • Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • A Study of Lifileucel with Cyclophosphamide, Fludarabine, and Aldesleukin for Adults with Previously Treated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of CD19-CAR_Lenti, Fludarabine, and Cyclophosphamide in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia or Aggressive B-Cell Lymphomas

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of gemtuzumab ozogamicin and chemotherapy combinations in children with newly diagnosed acute myeloid leukemia, high-risk myelodysplastic syndrome, or myeloid sarcoma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Ireland

  • Study on Treosulfan, Fludarabine Phosphate, and Thiotepa for Patients with Myelofibrosis Undergoing Haplo-identical Transplantation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria France Germany Italy Spain

  • Study of venetoclax with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed patients with intermediate or high-risk Acute Myeloid Leukemia

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Fludarabine Phosphate: A chemotherapy drug used to treat various types of blood cancers. It works by interfering with the growth of cancer cells.
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells called lymphocytes, typically progressing slowly over time.
  • Non-Hodgkin's Lymphoma (NHL): A group of blood cancers that develop from lymphocytes, a type of white blood cell.
  • Indolent Lymphoma: A slow-growing type of lymphoma that tends to progress gradually over many years.
  • Autologous Hematopoietic Stem Cell Transplantation (AHSCT): A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to rebuild the immune system.
  • Conditioning Regimen: A treatment plan, usually involving chemotherapy and/or radiation, used to prepare a patient's body for stem cell transplantation.
  • Response Rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Immunosuppressive Therapy: Treatment that lowers the activity of the body's immune system, often used in transplantation to prevent rejection of transplanted organs or cells.

References

  1. https://clinicaltrials.gov/study/NCT00688883
  2. https://clinicaltrials.gov/study/NCT01124526
  3. https://clinicaltrials.gov/study/NCT00185445
  4. https://clinicaltrials.gov/study/NCT00582933